Previous 10 | Next 10 |
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal f...
Signaling its determination to close the deal amid rival offers, AcelRx Pharmaceuticals ( ACRX -4.0% ) has increased its bid for Tetraphase Pharmaceuticals ( TTPH -8.3% ) to $30M in cash and stock plus an additional $14.5M in cash payable under a contingent value right (CVR). More news...
REDWOOD CITY, Calif. , May 27, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of ...
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA ™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into an amendment to the Agreement ...
Merger activity remained stuck in neutral last week with no new deals announced and no deals closing. We did have one deal enter into litigation, and arbitrageurs are watching it closely to see if the courts can force the acquiring company to close the deal on the original terms. There were ...
I have covered AcelRx Pharmaceuticals ( ACRX ) before, so investors should view this as an update to my previous articles . Last summer, some readers may have watched a documentary about the race to the moon. I did, and one thing that I keep remembering is the pictures of the large lunar ...
These Penny Stocks Took May By Storm & Just Made New Highs This Week The funny thing about penny stocks – maybe not that funny – is they can produce short-term, mid-term, and long-term gains. While most fall into the first two categories, we’ve seen certain penny sto...
Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +161% on positive Tc99m tilmanocept data in rheumatoid arthritis. More news on: Navidea Biopharmaceuticals, Inc., Medigus Ltd., Digirad Corporation, Stocks on the move, , Read more ...
The board of Tetraphase Pharmaceuticals (NASDAQ: TTPH ) has determined that the recent acquisition offer of up to $39.5M in upfront cash and a potential CVR payout from Melinta Therapeutics (NASDAQ: MLNT ) is superior to the previously-agreed-to all-stock deal valued at ~$14.4M fr...
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has determined that the lates...
News, Short Squeeze, Breakout and More Instantly...
Tetraphase Pharmaceuticals Inc. Company Name:
TTPH Stock Symbol:
NASDAQ Market:
Tetraphase Pharmaceuticals Inc. Website:
SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disease...
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases SAN DIEGO, Ca...
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an uns...